Big Pharma derives its oligopoly from the barriers to entry that the FDA imposes. Presumably they take every opportunity to lobby for more rigorous extensive te

Big Pharma derives its oligopoly from the barriers to entry that the FDA imposes. Presumably they take every opportunity to lobby for more rigorous extensive testing. Not because they want to pay more to run tests, but because they want their smaller competitors to pay more to run studies for drugs that might compete. This is, of course, not an explanation for how they have variously captured the components of the FDA, but it does explain how such a capture is an explanation for foot-dragging.